FKBP52 modulates pathological Tau activity in spinal primary motoneurons. (A–C) Lateral views of 48-hpf control embryos and FKBP52 morphant. Lateral views of znp1 antibody staining of control (D), FKBP52 morphant (E), Huc-Tau (F), and Huc-Tau injected with either FKBP52 MO (G) or FKBP52 mRNA (H) are shown at 48 hpf. (D2–H2) Tracings of motor-axon tracts ventral to the spinal cord derived from the panels directly above. In all images, anterior is to the left and dorsal is to the top. (Scale bars: A–C, 200 µm; D2–H2, 100 µm.) (I) Bar chart depicts the difference in the percentage of axons that reach their most ventral target. No significant difference is observed between WT and Huc-Tau + FKBP52MO embryos (N.S, P > 0.05; *P < 0.05; **P < 0.01). N.S, nonsignificant.
|